Allergan
Allergan, officially known as Allergan plc, is a prominent global pharmaceutical company headquartered in the United States. Founded in 1948, Allergan has established itself as a leader in the biopharmaceutical industry, focusing on areas such as medical aesthetics, eye care, and neuroscience. The company is renowned for its innovative products, including the widely recognised Botox, which has transformed both cosmetic and therapeutic treatments. With major operational regions spanning North America, Europe, and Asia, Allergan has achieved significant milestones, including its acquisition by AbbVie in 2020, further solidifying its market position. The company’s commitment to research and development has led to a diverse portfolio of unique offerings, making it a key player in enhancing patient outcomes and quality of life.
DitchCarbon Score
How does Allergan's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan's score of 20 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Allergan's reported carbon emissions
In 2017, Allergan reported total carbon emissions of approximately 250,000,000 kg CO2e across all scopes, with specific emissions of about 88,190,000 kg CO2e from Scope 1 and approximately 46,800,000 kg CO2e from Scope 2. The company has not disclosed any specific reduction targets or initiatives related to carbon emissions, nor has it committed to the Science Based Targets initiative (SBTi). Historically, Allergan's emissions have shown fluctuations, with a notable increase in Scope 1 emissions from about 23,423,000 kg CO2e in 2010 to 88,190,000 kg CO2e in 2017. The company has not provided data on Scope 3 emissions for the most recent years, but it has consistently reported significant emissions in this category, reaching 250,000,000 kg CO2e in 2015, 2016, and 2017. Allergan's climate commitments remain vague, lacking specific reduction targets or detailed initiatives to address its carbon footprint. As a major player in the pharmaceutical industry, the company faces increasing pressure to enhance its sustainability practices and align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergan is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
